Doxorubicin and Ifosfamide Treatment for Advanced Soft-Tissue Sarcoma
Author Information
Author(s): G. F. G. Almeida, G. Jr. Castro, I. M. L. Snitcovsky, S. A. Siqueira, E. H. Akaishi, O. P. Camargo, C. R. G. C. M. Oliveira, M. H. H. Federico
Primary Institution: Universidade de Sao Paulo
Hypothesis
Can a sequential dose-dense chemotherapy regimen improve outcomes in high-grade soft-tissue sarcoma patients?
Conclusion
The sequential dose-dense chemotherapy regimen should not be routinely used due to high toxicity, but may benefit selected patients.
Supporting Evidence
- Response rate was 15% with three partial responses observed.
- Grade 3/4 toxicities occurred in 18 patients.
- Patients younger than 45 years with locally advanced disease had longer survival.
Takeaway
Doctors tested a new way to give medicine to patients with a type of cancer, but it made many people very sick, so they need to be careful about who gets it.
Methodology
Patients received three cycles of doxorubicin followed by three cycles of ifosfamide, with GCSF support.
Potential Biases
The study was conducted at a single institution, which may introduce bias.
Limitations
The study had a small sample size and a low response rate, limiting the ability to draw firm conclusions.
Participant Demographics
Median age was 39 years, with 60% male and 40% female participants.
Statistical Information
P-Value
0.0005
Confidence Interval
95% CI 0.04–0.43
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website